Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 85, Issue 2, 2009, Pages 147-152

  Aso, Yoshimasa ^a   Hara, Kenji ^a   Ozeki, Noriyuki ^a   Yatsuka, Chikako ^a   Nakano, Tomoki ^a   Matsumoto, Sachiko ^a   Suetsugu, Mariko ^a   Nakamachi, Takafumi ^a   Takebayashi, Kohzo ^a   Haruki, Kohsuke ^a   Inukai, Toshihiko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Adiponectin; Hematocrit; High molecular weight; Peripheral edema; Pioglitazone

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; FEMALE; FLUID RETENTION; FOLLOW UP; GLYCEMIC CONTROL; HEMATOCRIT; HUMAN; JAPANESE; LOW DRUG DOSE; MALE; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADIPONECTIN; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; PATIENT SELECTION; SEX CHARACTERISTICS; THIAZOLIDINEDIONES;

EID: 67649842381     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.05.015     Document Type: Article

References (25)

1. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1111
2. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
3. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 29-33
4. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 26 (2005) 439-451
5. Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
6. Hirose H., Kawai T., Yamamoto Y., Taniyama M., Tomita M., Matsubara K., et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51 (2002) 31
7. Pajvani U.B., Du X., Combs T.P., Berg A.H., Rajala M.W., Schulthess T., et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J. Biol. Chem. 278 (2003) 9073-9085
8. Tsao T.S., Tomas E., Murrey H.E., Hug C., Lee D.H., Ruderman N.B., et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J. Biol. Chem. 278 (2003) 50810-50817
9. Waki H., Yamauchi T., Kamon J., Ito Y., Uchida S., Kita S., et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J. Biol. Chem. 278 (2003) 40352-40363
10. Aso Y., Yamamoto R., Suetsugu M., Matsumoto S., Wakabayashi S., Matsutomo R., et al. Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes. Diabet. Med. 24 (2007) 962-968
11. Satoh N., Ogawa Y., Usui T., Tagami T., Kono S., Uesugi H., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26 (2003) 2493-2497
12. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
13. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355 (2006) 2427-2443
14. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108 (2003) 2941-2948
15. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., and Schneider R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23 (2000) 1605-1611
16. Majima T., Komatsu Y., Doi K., Shigemoto M., Takagi C., Fukao A., et al. Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. Endocr. J. 53 (2006) 325-330
17. Aso Y., Yamamoto R., Wakabayashi S., Uchida T., Takayanagi K., Takebayashi K., et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55 (2006) 1954-1960
18. Miyazaki Y., Matsuda M., and DeFronzo R.A. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25 (2002) 517-523
19. Ibáñez L., López-Bermejo A., Díaz M., Enríquez G., Valls C., and de Zegher F. Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. Clin. Endocrinol. (Oxf.) 68 (2008) 317-320
20. Xu A., Chan K.W., Hoo R.L., Wang Y., Tan K.C., Zhang J., et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J. Biol. Chem. 280 (2005) 18073-18080
21. Waugh J., Keating G.M., Plosker G.L., Easthope S., and Robinson D.M. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 66 (2006) 85-109
22. Hong G., Lockhart A., Davis B., Rahmoune H., Baker S., Ye L., et al. PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells. FASEB J. 17 (2003) 1966-1968
23. Guan Y., Hao C., Cha D.R., Rao R., Lu W., Kohan D.E., et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11 (2005) 861-866
24. Kiryluk K., and Isom R. Thiazolidinediones and fluid retention. Kidney Int. 72 (2007) 762-768
25. Yang T., and Soodvilai S. Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res. 2008 (2008) 943614